Cepheid has released performance data for its Xpert HPV, currently in clinical trials with a targeted CE-IVD release this year. “We’re pleased with the early Xpert HPV data that highlight Cepheid’s commitment to delivering tests that offer the unmatched combination of performance, ease of use and speed that our customers expect,” said John Bishop, Cepheid’s chairman and CEO.
(Image: National Cancer Institute/Laboratory of Tumor Virus Biology)
“Highlighting Cepheid’s history of innovation, the GeneXpert system delivers the ‘sample-in, answer-out’ molecular testing solution that defines the essential capability for broad market dissemination that many others are aspiring to bring to market,” continued Mr Bishop. “Our GeneXpert System now has an installed base of more than 5000 systems in 139 countries, with a menu of 14 available Xpert tests spanning healthcare-associated infections, critical infectious disease and sexual health.” Xpert HPV is a multiplexed test that targets the E6/E7 region of 14 cancer-related HPV types, specifically types 16 and 18/45 in separate detection channels, with 11 other high-risk types detected in combined channels.
www.cepheid.com